Suppr超能文献

中心和个体对来自丙型肝炎供体的心脏和肺脏的考虑意愿。

Center and Individual Willingness to Consider Heart and Lung Offers From Donors With Hepatitis C.

机构信息

Division of Thoracic Surgery, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.

Division of Transplant Surgery, Department of Surgery, New York University Grossman School of Medicine and Langone Health, New York, New York.

出版信息

J Surg Res. 2024 Oct;302:175-185. doi: 10.1016/j.jss.2024.07.043. Epub 2024 Aug 3.

Abstract

INTRODUCTION

Transplants with hearts and lungs from donors with hepatitis C virus (HCV D+) have been proven safe and effective since development of direct-acting antivirals, yet the presence of HCV + persists as a reason to decline organs.

METHODS

We identified adult candidates listed January 1, 2015-March 8, 2023 for heart or lung transplant using the Scientific Registry of Transplant Recipients. We identified individual-level and center-level characteristics associated with listing to consider HCV D+ offers using multilevel logistic regression in a multivariable framework.

RESULTS

Over the study period, the annual percentage of candidates willing to consider HCV D+ offers increased for both heart (9.5%-74.3%) and lung (7.8%-59.5%), as did the percentage of centers listing candidates for HCV D+ heart (52.9%-91.1%) and lung (32.8%-82.8%) offers. Candidates at centers with more experience with HCV D+ transplants were more likely to consider HCV D+ organ offers. After adjustment, listing center explained 70% and 78% of the residual variance in willingness to consider HCV D+ hearts and lungs, respectively.

CONCLUSIONS

Although listing for consideration of HCV D+ offers has increased, it varies by transplant center. Center-level barriers to consideration of HCV D+ organs reduce recipients' transplant access.

摘要

简介

自直接作用抗病毒药物问世以来,从丙型肝炎病毒(HCV D+)供体中移植的心脏和肺脏已被证明是安全有效的,但 HCV+的存在仍然是拒绝器官的一个原因。

方法

我们使用移植受者科学登记处,确定了 2015 年 1 月 1 日至 2023 年 3 月 8 日期间列出的接受心脏或肺脏移植的成年候选者。我们确定了与列出 HCV D+供体相关的个体和中心特征,以便在多变量框架中使用多水平逻辑回归来考虑 HCV D+的供体。

结果

在研究期间,无论是心脏(9.5%-74.3%)还是肺脏(7.8%-59.5%),愿意考虑 HCV D+供体的候选者的比例每年都有所增加,同时愿意列出 HCV D+心脏(52.9%-91.1%)和肺脏(32.8%-82.8%)供体的中心比例也有所增加。在有更多 HCV D+移植经验的中心的候选者更有可能考虑 HCV D+器官供体。调整后,中心解释了愿意考虑 HCV D+心脏和肺脏的 70%和 78%的剩余方差。

结论

尽管考虑 HCV D+供体的意愿有所增加,但这因移植中心而异。考虑 HCV D+器官的中心障碍减少了受者的移植机会。

相似文献

2
Racial and Gender Disparities in Transplantation of Hepatitis C+ Hearts and Lungs.肝肺移植中丙肝阳性患者的种族和性别差异。
J Heart Lung Transplant. 2024 May;43(5):780-786. doi: 10.1016/j.healun.2023.12.012. Epub 2023 Dec 30.

本文引用的文献

9
OPTN/SRTR 2018 Annual Data Report: Hepatitis C.OPTN/SRTR 2018 年度数据报告:丙型肝炎。
Am J Transplant. 2020 Jan;20 Suppl s1:542-568. doi: 10.1111/ajt.15679.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验